178 related articles for article (PubMed ID: 10881054)
1. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
[TBL] [Abstract][Full Text] [Related]
2. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
3. High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma.
Baldissera RC; Aranha JF; Oliveira GB; Vigorito AC; Eid KA; Miranda EC; De Souza CA
Braz J Med Biol Res; 2002 Jan; 35(1):49-57. PubMed ID: 11743614
[TBL] [Abstract][Full Text] [Related]
4. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
5. High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow.
Santini G; De Souza C; Congiu AM; Nati S; Marino G; Soracco M; Sertoli MR; Rubagotti A; Spriano M; Vassallo F; Rossi E; Vimercati R; Piaggio G; Figari O; Benvenuto F; Abate M; Truini M; Ravetti JL; Ribizzi I; Damasio E
Leuk Lymphoma; 1999 Apr; 33(3-4):321-30. PubMed ID: 10221512
[TBL] [Abstract][Full Text] [Related]
6. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
7. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide.
Ghielmini M; Van der Bosch S; Bosshard M; Pampallona S; Gabutti L; Egger HP; Kiess M; Cavalli F; Sessa C
Cancer Chemother Pharmacol; 2001 Jun; 47(6):532-6. PubMed ID: 11459207
[TBL] [Abstract][Full Text] [Related]
11. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
[TBL] [Abstract][Full Text] [Related]
12. A risk-benefit assessment of amifostine in cytoprotection.
Mabro M; Faivre S; Raymond E
Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
[TBL] [Abstract][Full Text] [Related]
13. Protection by amifostine of cyclophosphamide-induced myelosuppression.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
[TBL] [Abstract][Full Text] [Related]
14. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
Woolley PV; Ayoob MJ; Smith FP; Dritschilo A
J Clin Oncol; 1983 Mar; 1(3):198-203. PubMed ID: 6321681
[TBL] [Abstract][Full Text] [Related]
16. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
17. [Amifostine: current and future applications in cytoprotection].
Lenoble M
Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
[TBL] [Abstract][Full Text] [Related]
18. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.
Capelli D; Santini G; De Souza C; Poloni A; Marino G; Montanari M; Lucesole M; Brunori M; Massidda D; Offidani M; Leoni P; Olivieri A
Br J Haematol; 2000 Aug; 110(2):300-7. PubMed ID: 10971385
[TBL] [Abstract][Full Text] [Related]
19. Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide.
Grdina DJ; Hunter N; Kataoka Y; Murley JS; Milas L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):22-7. PubMed ID: 10348256
[TBL] [Abstract][Full Text] [Related]
20. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
